SPDL1 and neoplasm: Since sPD-L1 is also released from non-tumor cells to maintain the immune response, our model system may remove sPD-L1, which is involved in physiological homeostasis of the immune response, leading to dysregulation of autoimmune responses as immune-related adverse events caused by checkpoint inhibitors [31].